Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
复制标题
DOI：
10.1038/nrd4309
复制
发表时间：
2014-06-01
影响因子：
120.1
通讯作者：
Pangalos, Menelas N.
中科院分区：
文献类型：
--
作者：
Cook, David;Brown, Dearg;Pangalos, Menelas N.
在可持续水平上维持研发（R＆D）生产力是当前面临制药行业面临的主要挑战之一。在本文中，我们讨论了2005年至2010年对阿斯利康小分子毒品项目的全面纵向审查的结果。该分析使我们能够基于项目成功和管道质量的五个最重要的技术决定因素建立框架，我们形容为五个“ R：正确的目标，正确的患者，正确的组织，正确的安全性和正确的商业潜力。第六个因素 - 正确的文化 - 对于基于这些技术决定因素鼓励有效决策至关重要。阿斯利康目前正在应用此框架来指导其研发团队，尽管现在证明这是否提高了公司的研发生产率还为时过早，但我们在这里介绍我们的数据和分析，希望它可以协助整个行业解决问题。这个关键挑战。
Maintaining research and development (R& D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry. In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-molecule drug projects from 2005 to 2010. The analysis allowed us to establish a framework based on the five most important technical determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right commercial potential. A sixth factor-the right culture-is also crucial in encouraging effective decision-making based on these technical determinants. AstraZeneca is currently applying this framework to guide its R& D teams, and although it is too early to demonstrate whether this has improved the company's R& D productivity, we present our data and analysis here in the hope that it may assist the industry overall in addressing this key challenge.